Halia Therapeutics Inc. has disclosed serine/threonine-protein kinase Nek7 inhibitors reported to be useful for the treatment of cancer, asthma, obesity, type 2 diabetes, hepatitis, peritonitis, neurodegeneration and psoriasis, among others.
Angion Biomedica Corp. has synthesized prodrugs of terevalefim acting as hepatocyte growth factor (HGF) mimetics and reported to be useful for the treatment of renal ischemia-reperfusion and lung injury.
Sunovion Pharmaceuticals Inc. has identified chroman and benzofuran derivatives acting as 5-HT1A and trace amine-associated receptor 1 (TAAR1) agonists reported to be useful for the treatment of depression.
Kawasaki Gakuen has divulged pyrrole-imidazole polyamides acting as transmembrane 4 L6 family member 1 (TM4SF1) and TMEM132b expression inhibitors reported to be useful for the treatment of cancer metastasis.
Inipharm Inc. has divulged thiazoles/isothiazoles acting as 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13) inhibitors reported to be useful for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, cirrhosis, alcoholic liver disease, drug-induced liver injury and portal hypertension.
Stanford University and Acurex Therapeutics Corp. have discovered voltage-dependent T-type calcium channel subunit α-1H (Cav3.2) blockers reported to be useful for the treatment of neurodegeneration.
Standigm Inc. has disclosed leucine-rich repeat kinase 2 (LRRK2), particularly LRRK2 G2019S mutant, inhibitors reported to be useful for the treatment of cancer, neurodegeneration, rheumatoid arthritis, tuberculosis, axial spondyloarthritis, radiographic (ankylosing spondylitis), Crohn's disease and dyskinesia.
RSS